Main Products/ Services/ Pipelines & Platforms
Pipelines▪ FLT3 Kinase Inhibitor ： Highly selective and potent against FLT3 and FLT3 mutants with superior tolerance in preclinical tox study. ▪ Raf Kinase Inhibitor IND ready. Highly selective, potent cytotoxicity to cancer cells with BRAF mutation. ▪ Anti-CD73 Antibody Long-lasting inhibition to CD73 enzyme activity showing superior anti-tumor activity than the benchmark. ▪ PD-L1/TIM-3/CSF-1R Antibodies Unique CDR sequences and different binding epitopes from competitors featuring high affinity and in vitro activity. ▪ RAS-PROTAC Conspicuous inhibition to various KRAS mutation types with KRAS degrader. ▪ Globo H/IO Blocker CAR-T Cells for Solid Tumor Enhancement of Globo H-specific CAR-T cells activity by PD-L1 antibody to overcome PD-1/PD-L1-mediated immunosuppression in solid tumor. ▪ CHO-C High Yield Protein Drug Platform Cell line development service with proprietary CHO-C cell lines offering high productivity and cost-effective solution to Biopharma.
Service▪ Antibody Generation, Production, and Characterization. ▪ Small Molecule Synthesis Platform ▪ Preclinical Pharmacology ▪ Preclinical ADME / DMPK ▪ Drug Analysis & Formulation ▪ Toxicology Pilot Study & Consultation Service ▪ mRNA and LNP Production ▪ Oligonucleotide Synthesis and Production ▪ BD service to help in looking for license possibility, IP strategy /analysis, Market & Competitive Analysis
DCB is a non-profit research institute that focuses on pre-IND stage drug development. We welcome partners for cooperation to advance our pipelines to clinical trials and commercialization. We are also seeking licenses out of our high-potential targets.